SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-20-009167
Filing Date
2020-03-06
Accepted
2020-03-06 16:05:47
Documents
14
Period of Report
2020-03-03
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rare-8k_20200303.htm   iXBRL 8-K 41454
2 EX-10.1 rare-ex101_44.htm EX-10.1 106762
3 GRAPHIC gutqvup1twdo000001.jpg GRAPHIC 348834
  Complete submission text file 0001564590-20-009167.txt   776999

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA rare-20200303.xsd EX-101.SCH 5784
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE rare-20200303_lab.xml EX-101.LAB 18721
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rare-20200303_pre.xml EX-101.PRE 11179
13 EXTRACTED XBRL INSTANCE DOCUMENT rare-8k_20200303_htm.xml XML 3414
Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Filer) CIK: 0001515673 (see all company filings)

IRS No.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36276 | Film No.: 20694775
SIC: 2834 Pharmaceutical Preparations